Search research articles
Contact Us
Filters
Showing results (231-240 of 236) with videos related to
Page
of 24
Sort By:
You have reached the last page of results.
This site can display upto 236 results.
The Journal of Biological Chemistry
|
January 25, 1992
Two naturally occurring mutations at the first and second bases of codon aspartic acid 156 in the proposed catalytic triad of human lipoprotein lipase. In vivo evidence that aspartic acid 156 is essential for catalysis
Y H Ma, T Bruin, S Tuzgol, et al.
Journal of Lipid Research
|
August 1, 1990
Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia
T L Innerarity, R W Mahley, K H Weisgraber, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology
|
November 5, 1997
Efficacy and safety of a new hydroxymethylglutaryl-coenzyme A reductase inhibitor, atorvastatin, in patients with combined hyperlipidemia: comparison with fenofibrate
T C Ooi, T Heinonen, P Alaupovic, et al.
Journal of Medical Genetics
|
August 19, 2008
A PCSK9 variant and familial combined hyperlipidaemia
M Abifadel, L Bernier, G Dubuc, et al.
JAMA
|
January 10, 1996
Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia
R G Bakker-Arkema, M H Davidson, R J Goldstein, et al.
Clinical Genetics
|
July 1, 1997
Geographic distribution of French-Canadian low-density lipoprotein receptor gene mutations in the Province of Quebec
M C Vohl, S Moorjani, M Roy, et al.
Page
of 24
Search research articles
Search
Showing results (231-240 of 236) with videos related to
Sort By:
Page
of 24
You have reached the last page of results.
This site can display upto 236 results.
The Journal of Biological Chemistry
|
January 25, 1992
Two naturally occurring mutations at the first and second bases of codon aspartic acid 156 in the proposed catalytic triad of human lipoprotein lipase. In vivo evidence that aspartic acid 156 is essential for catalysis
Y H Ma, T Bruin, S Tuzgol, et al.
Journal of Lipid Research
|
August 1, 1990
Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia
T L Innerarity, R W Mahley, K H Weisgraber, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology
|
November 5, 1997
Efficacy and safety of a new hydroxymethylglutaryl-coenzyme A reductase inhibitor, atorvastatin, in patients with combined hyperlipidemia: comparison with fenofibrate
T C Ooi, T Heinonen, P Alaupovic, et al.
Journal of Medical Genetics
|
August 19, 2008
A PCSK9 variant and familial combined hyperlipidaemia
M Abifadel, L Bernier, G Dubuc, et al.
JAMA
|
January 10, 1996
Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia
R G Bakker-Arkema, M H Davidson, R J Goldstein, et al.
Clinical Genetics
|
July 1, 1997
Geographic distribution of French-Canadian low-density lipoprotein receptor gene mutations in the Province of Quebec
M C Vohl, S Moorjani, M Roy, et al.
Page
of 24